Initiate the JIVE open-label extension trial and a pediatric MAD trial in FA patients
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Mar 2021
- Due
- 31 Dec 2021
- Delivered
- January 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“remain on track to initiate our open-label extension, the JIVE trial, and a pediatric MAD trial in FA patients during the second half of the year”
What we found
Evidence strength A What the grades mean
The company planned to initiate the open-label extension trial in the second half of 2023, but filings indicate the trial was initiated in January 2024.
-
A Larimar Therapeutics, Inc. 10-K filed 2024-03-14
“In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 4 Mar 2021
Deadline 31 Dec 2021 (“during the second half of the year”) · wording firm
-
Version 2 · stated 9 Jan 2023
Deadline 31 Dec 2023 (“2H 2023”) · wording expected
“Initiation currently planned for 2H 2023”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- JIVE open-label extension and pediatric MAD trial in FA patients
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LRMR-025148 · Corrections policy